Document Detail


Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary heart disease in patients with essential hypertension.
MedLine Citation:
PMID:  9468449     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Besides hypertension, several cardiovascular risk factors can play a role in the development of coronary heart disease (CHD) in hypertensive patients. Lipoprotein(a) [Lp(a)] is an important and independent cardiovascular risk factor, but its role in the development of CHD in hypertensives has not been studied. OBJECTIVE: To investigate whether or not Lp(a) levels and isoforms of apolipoprotein(a) [apo(a)] are predictors of CHD in patients with essential hypertension. METHODS: Lp(a) levels and apo(a) polymorphism were evaluated in 249 patients with essential hypertension, in 142 non-hypertensive patients with CHD and in 264 healthy controls. RESULTS: Hypertensives with CHD (n = 61) had Lp(a) levels [19 (range 0.5-73.5) versus 7 mg/dl (range 0-83.5), P < 0.001] and a percentage of apo(a) isoforms of low (< 655 kDa) relative molecular mass (RMM, 59.2 versus 25.9%, P < 0.001) higher than did those without CHD (n = 188). Moreover, there were more subjects with at least one apo(a) isoform of low RMM in the subgroup of patients with CHD than there were in that of those without CHD (80.3 versus 30.8%, P< 0.001). Lp(a) levels and apo(a) polymorphism did not differ significantly between hypertensive and non-hypertensive patients with CHD. Stepwise regression analysis indicated that high Lp(a) levels (P= 0.002073) and particularly the presence of at least one apo(a) isoform of low RMM (P < 0.000001) are strong predictors of CHD in hypertensive patients. CONCLUSIONS: Our data show that high Lp(a) levels and the presence of at least one apo(a) isoform of low RMM are strong and independent genetic risk factors for CHD in hypertensive patients. These findings suggest that Lp(a) and apo(a) isoforms should be assessed together with other cardiovascular risk factors to establish the overall CHD risk status of each hypertensive patient
Authors:
C Gazzaruso; P Buscaglia; A Garzaniti; C Falcone; S Mariotti; S Savino; G Bonetti; G Finardi; D Geroldi
Related Documents :
2142489 - Improved results with surgical treatment of renovascular hypertension: an individualize...
2006659 - Adverse treatment effects in the trial of the european working party on high blood pres...
8811569 - External compression as initial management of giant omphaloceles.
10773149 - The significance of sinistral portal hypertension complicating chronic pancreatitis.
11133249 - Obstructive sleep apnea and hypertension: are peripheral chemoreceptors involved?
21520119 - Idiopathic ulcerative laryngitis.
12165819 - Assessment of the afferent vagal nerve in patients with gastroesophageal reflux.
24573739 - Ultrasonographic measurement of femoral cartilage thickness in acromegalic patients.
3619169 - Intravenous use of glycopyrrolate in acute respiratory distress due to bronchospastic p...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of hypertension     Volume:  15     ISSN:  0263-6352     ISO Abbreviation:  J. Hypertens.     Publication Date:  1997 Mar 
Date Detail:
Created Date:  1998-03-12     Completed Date:  1998-03-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8306882     Medline TA:  J Hypertens     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  227-35     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine and Medical Therapeutics, IRCCS Policlinico San Matteo, University of Pavia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Apolipoproteins / genetics*
Apoprotein(a)
Coronary Disease / blood*,  genetics*
Female
Homozygote
Humans
Hypertension / blood*,  genetics*
Lipoprotein(a) / blood*
Male
Middle Aged
Phenotype
Polymorphism, Genetic
Chemical
Reg. No./Substance:
0/Apolipoproteins; 0/Lipoprotein(a); EC 3.4.21.-/Apoprotein(a)

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Underestimation of the true benefits of antihypertensive treatment: an assessment of some important ...
Next Document:  The effect of alternative criteria for hypertension on estimates of prevalence and control.